ELOS Stock News 10.54 05/13/2014 07:16:12 Syneron Medical Ltd

New Post Public Reply Private Reply Replies (0) Message Board

May 13, 2014 at 8:16 AM

Syneron Medical Ltd (ELOS) 10.54 $ELOS

Syneron Candela Achieves Approval to Market Its ALEX II System in Japan For Treatment of Benign Dermal Lesions
PR Newswire Europe - Mon Apr 28, 7:01PM CDT
TOKYO, April 29, 2014 /PRNewswire/ --

Syneron Medical to Report First Quarter 2014 Financial Results on May 14, 2014
PR Newswire - Thu Apr 24, 7:00AM CDT
Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced that it will release first quarter 2014 financial results before the market opens on Wednesday, May 14, 2014. The earnings release will be available on Syneron's website at www.investors.syneron.com.

ABIOMED Up on License from Opsens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 2:20PM CDT
In a few trading sessions following the announcement, shares of ABIOMED climbed approximately 4.0% to close at $24.95 yesterday.

Balanced Outlook on Accuray - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 1:50PM CDT
Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter.

What Falling Estimates & Price Mean for Opko Health (OPK) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:53AM CDT
Opko has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

ABIOMED's Impella RP Bags CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:50PM CDT
Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.

Accuray Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 1:50PM CDT
Accuray's year-over-year loss narrowed primarily due to robust top-line improvement of 20% from the year-ago period.

Syneron to Host Conference Call and Webcast to Discuss UltraShape FDA Clearance
PR Newswire - Wed Apr 16, 9:46AM CDT
Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today details for its previously announced conference call and webcast to discuss the United States Food and Drug Administration (FDA) 510(k) clearance of the UltraShape(TM) System for selective non-invasive fat cell destruction for the purpose of body contouring.

The New Wave in Covidien's Endoscopic Devices - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 2:00PM CDT
Shares of Covidien rose 1.3% in the trading session following the news release and closed at $69.92 yesterday.

Balanced View of Luminex Corporation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 5:30PM CDT
Luminex is optimistic about the life science research market and foresees continued favorable trends with respect to demand from its clinical customers.

Varian Medical Systems Settles Patent Dispute - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 2:10PM CDT
According to VAR, part of the settlement will be expensed in the financial results of the second quarter while the balance will be recorded as a prepaid royalty in the third quarter of fiscal 2014.

Syneron Receives US FDA Clearance to Market the UltraShape System for Fat Cell Destruction
PR Newswire Europe - Mon Apr 14, 8:03AM CDT
IRVINE, California, April 14, 2014 /PRNewswire/ --

BioTime, Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc.
Business Wire - Mon Apr 14, 8:02AM CDT
BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors.

Weakness Seen in AngioDynamics (ANGO): Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 7:43AM CDT
AngioDynamics falls 7.8% last trading session, continuing the downtrend

AngioDynamics Q3 Earnings Flat but Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:28AM CDT
ANGO lowered its adjusted EPS guidance for fiscal 2014 to a range of 60 to 63 cents from the prior range of 63 to 67 cents.

Delcath Systems (DCTH) Worth Watching: Stock Soars 20.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:25AM CDT
Delcath Systems was a big mover last session, with shares surging over 20% on the day.

Masimo Reports Encouraging PVI Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 5:40PM CDT
The results demonstrated that MASI's non-invasive PVI parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...